Results 181 to 190 of about 95,506 (252)

[Laboratory markers of the reactogenicity of smallpox vaccines].

Voprosy virusologii, 1972
S S, Marennikova, I A, Svet-Moldavskaia, N M, Mal'tseva   +2 more
openaire   +1 more source

Glycoengineered Recombinant Alpha1‐Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma‐Derived Protein

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Alpha‐1‐antitrypsin (A1AT) is a multifunctional, clinically important, high‐value therapeutic glycoprotein that can be used for the treatment of many diseases, such as A1AT deficiency, diabetes, graft‐versus‐host disease, cystic fibrosis, and various viral infections. Currently, the only U.S. food and drug administration‐approved treatment for
Frances Rocamora, Chen‐Lin Hsieh, Sanne Schoffelen, Johnny Arnsdorf, Eric A. Toth, Abdul S. Yunus, Thomas E. Cleveland IV, Sara Petersen Bjørn, Mina Ying Min Wu, Noel G. McElvaney, Bjørn Gunnar Rude Voldborg, Thomas R. Fuerst, Nathan E. Lewis   +12 more
wiley   +1 more source

Protective Efficacy of a Modified Vaccinia Ankara-Based Vaccine Against Zika. [PDF]

Vaccines (Basel)
Carvajal Aristizabal L, Hoyos Ramírez I, Camacho E, Maldonado D, Marín E, Hernández-Ortiz JP, Osorio JE.   +6 more
europepmc   +1 more source

Enhancing the Secretion Systems: Genetic Engineering of Super Bioagents for Effective Plant Disease Control

Biotechnology and Bioengineering, EarlyView.
Genetic engineering (GE) overcomes BCA limits, enabling robust, scalable crop protection. “Super Bioagents” (SBs) use optimized SSs to enhance bioactive molecule delivery. Optimizing SSs enhance precise, sustainable effector deployment for stable disease suppression. SBs use microbiome‐informed design for scalable, next‐gen sustainable crop protection.
Michael Dare Asemoloye
wiley   +1 more source

Antigen-specific Th1 cytokine markers and protection against tuberculosis: a systematic review and meta-analysis stratified by progression to active disease and sustained IGRA conversion. [PDF]

Front Cell Infect Microbiol
Lin T, Liu S, Pan YY.
europepmc   +1 more source

Inventory Replenishment and Transshipment for Distributed Autologous Cell Therapy Manufacturing Networks

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Autologous cell therapy (AuCT) manufacturing networks must balance two competing objectives: reducing cost and improving patient access to time‐sensitive therapy. This study compares three AuCT manufacturing network designs: a centralized network with a single manufacturing facility, a coordinated point‐of‐care (POC) network in which POCs can ...
Zhaowei Li, Chelsea C. White III, Kan Wang, Ben Wang   +3 more
wiley   +1 more source

TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses. [PDF]

Vaccines (Basel)
Minosse C, Spezia PG, Belladonna S, Bettini A, Matusali G, Colavita F, Notari S, Petrone L, Tiberi M, Cavasio AR, Mazzotta V, Rosa L, Cimini E, Focosi D, Goletti D, Nicastri E, Antinori A, Maggi F.   +17 more
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Harnessing <i>Toxoplasma gondii</i> microneme proteins for serodiagnosis and vaccine development: a review. [PDF]

Ann Med
Ji Y, Wang Z, Feng Y, Ahmad I, Alzahrani KJ, Alsharif KF, Alzahrani FM, Zhao X, Qadeer A, Liu W.   +9 more
europepmc   +1 more source